ProCE Banner Events

Share

Psychiatry Summit 2024

Don’t miss our Third Annual Psychiatry Summit 2024! Join us for 2 full days of live, virtual cutting-edge programs! This conference—presented by world-renowned leading experts—sets the standard for timely, unbiased, evidence-based education.

Engage with experts from around the world as they discuss the latest advances in the diagnosis and treatment of a range of psychiatric illnesses, debate controversies in the field, and share their clinical pearls. Earn up to 10 hours of CME/CE credit.

Pharmacists: 10.00 contact hours (1 CEUs)

Physicians: maximum of 10.00 AMA PRA Category 1 Credits

Physician Assistants/Physician Associates: 10.00 AAPA Category 1 CME credits

Psychologists: 10.00 APA CE Credits

Nurse Practitioners/Nurses: 10.00 Nursing contact hours

Social Workers: 10.00 ASWB ACE CE Credits

Time and location

Friday, May 17, 2024 to Saturday, May 18, 2024

9:00 AM - 2:35 PM Eastern Time (ET)

Virtual

Faculty
Anita H. Clayton, MD, DLFAPA, IF

Wilford W. Spradlin Professor and Chair
Department of Psychiatry & Neurobehavioral Sciences
Professor of Clinical Obstetrics & Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia

Roger McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology
University of Toronto, Canada
Chairman and Executive Director, Brain and Cognition Discovery Foundation
Toronto, Canada
Board Chair, Depression and Bipolar Support Alliance
Board of Directors
Chicago, Illinois

Sanjay J. Mathew, MD

Professor and Vice Chair for Research
Baylor College of Medicine
Houston, Texas

Stanley N. Caroff, MD

Emeritus Professor of Psychiatry
University of Pennsylvania Perelman School of Medicine
Corporal Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
New York, New York
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany

Marwan Sabbagh, MD, FAAN, FANA

Moreno Family Chair for Alzheimer's Research
Vice Chairman for Research and Professor
Department of Neurology
Barrow Neurological Institute
Phoenix, Arizona

George R. Brown, MD, DFAPA

Professor and Associate Chairman for Veterans Affairs
Department of Psychiatry and Behavioral Sciences
East Tennessee State University
Johnson City, Tennessee

Brian Mohlenhoff, MD

Staff Psychiatrist, PTSD Clinical Team
San Francisco VA Healthcare System
Associate Program Director
San Francisco VA Medical Center Affairs
UCSF Psychiatry Residency
Training Program
HS Associate Clinical Professor
Department of Psychiatry and Behavioral Sciences,
UCSF Weill Institute for Neurosciences
San Francisco, California

Holly A. Swartz, MD

Professor of Psychiatry
Director, Center for Advanced Psychotherapy
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Scott A. Simpson, MD, MPH

Director, Division of Community, Population, and Public Mental Health
Associate Professor of Psychiatry
Department of Psychiatry
University of Colorado School of Medicine
Aurora, Colorado

Rahn Kennedy Bailey, MD, DFAPA, ACP

Kathleen & John Bricker Chair
Professor & Head
Department of Psychiatry
Assistant Dean, Diversity & Community Engagement
LSUHSC
Chairman, Board of Trustees
Cobb Research Institute
New Orleans, Louisiana

Agenda

Friday, May 17, 2024 ET

9:00 AM - 9:05 AM: Opening Remarks—by Holly A. Swartz, MD

9:05 AM - 10:05 AM: Medical and Mental Health Issues in Gender-Affirming Hormonal Treatments for Transgender and Gender Diverse Patients—presented by George R. Brown, MD, DFAPA

  • Transgender individuals often experience discrimination, poverty, social stigmatization, and marginalization, contributing to psychiatric illnesses. This session is designed to provide education on treatment considerations for psychiatric comorbidities and psychiatric and medical adverse events of gender-affirming hormonal treatments in transgender patients.

5-minute break

10:10 AM - 11:10 AM: Navigating a New Era of Targeted Treatments for Postpartum Depression—presented by Anita H. Clayton, MD, DLFAPA, IF

  • Targeted treatment options are now available for postpartum depression. The session will discuss screening and diagnostic strategies, pathophysiology hypotheses, and the latest clinical evidence for new and emerging treatment options in PPD, including pearls for use in clinical practice.

5-minute break

11:15 AM - 12:15 PM: Shadows of Wellness: Residual Symptoms in Major Depressive Disorder—presented by Sanjay J. Mathew, MD

  • This session delves into the often overlooked aspect of MDD: residual symptoms. We will unravel the complexities of lingering symptoms and explore innovative treatment pathways that offer renewed hope for individuals navigating the aftermath of depression. From emerging therapies to personalized interventions, this session aims to shed light on the challenges of residual symptoms while inspiring a deeper understanding of novel approaches.

5-minute break

12:20 PM - 1:20 PM: Calming the Storm: Understanding and Managing Agitation in Alzheimer’s Disease—presented by Marwan Sabbagh, MD, FAAN, FANA

  • This session will unravel the intricate mechanisms underlying agitation associated with Alzheimer’s disease. Dive deep into the neurobiological aspects that contribute to this challenging aspect of dementia. Furthermore, we will explore cutting-edge and novel treatments that are paving the way for more effective and compassionate care.

5-minute break

1:25 PM - 2:35 PM: Decoding Complexity: Best Practices in Identifying and Managing Bipolar Depression with DSM-5-TR Specifiers and Closing Remarks—presented by Roger McIntyre, MD, FRCPC

  • Bipolar depression identification and management can be confusing in the presence of the DSM-V-TR specifiers, including mixed features and anxious distress. This session will seek to clarify best practices for identification and management of bipolar depression with DSM-V-TR specifiers through interactive case-based discussions

 

Saturday, May 18, 2024 ET

9:00 AM - 9:05 AM: Opening Remarks—by Holly A. Swartz, MD

9:05 AM - 10:05 AM: Beyond the Breaking Point: Evaluation and Management of Patients in Crisis—presented by Scott A. Simpson, MD, MPH 

  • This session will delve into the intricate landscape of managing patients who have reached their breaking point, navigating through the complexities of psychiatric emergencies with empathy, skill, and evidence-based strategies. This session offers an in-depth exploration of the evaluation and management approaches essential for healthcare professionals confronted with individuals in acute distress.

5-minute break

10:10 AM - 11:10 AM: Moving Forward: Understanding Tardive Dyskinesia Across the Lifespan—presented by Stanley N. Caroff, MD

  • This session will focus on differential diagnosis, risk factors across disease states, and aspects of aging that make older patients at higher risk for TD. General treatment considerations for older populations and safety of VMAT2 inhibitors in these patients also will be covered.

5-minute break

11:15 AM - 12:15 PM: Cultivating Inclusivity: Paving the Path to Improved Diversity in Clinical Trials—presented by Rahn Kennedy Bailey, MD, DFAPA, ACP

  • This session will explore the critical importance of improving diversity and inclusivity in clinical trials so the results are generalizable and applicable to real-world patients encountered in clinical practice. Through insightful conversations and real-world examples, we aim to inspire a shift toward greater diversity, ensuring that clinical trials reflect the rich tapestry of the patient populations being treated.

5-minute break

12:20 PM - 1:20 PM: Navigating the Frontier of Schizophrenia Treatment: Unveiling Innovations and Ensuring Patient Well-being—presented by Christoph U. Correll, MD

  • This interactive symposium will help learners improve their practice by providing education on unmet needs in current schizophrenia treatment, including monitoring parameters and how novel agents address both symptoms and common adverse events seen with traditional schizophrenia treatment.

5-minute break

1:25 PM - 2:35 PM: Breaking Ground: Exploring the Horizon of Emerging Treatments for PTSD and Closing Remarks—presented by Brian Mohlenhoff, MD

  • Unlock the intricacies of PTSD in this session, which will be a deep dive into the mechanisms underlying posttraumatic stress disorder, providing a comprehensive understanding of how trauma affects the mind and body. We will explore the nuanced methods of identifying PTSD, shedding light on early recognition and diagnosis. The talk also will spotlight the latest in emerging treatment options currently on the horizon.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 10.0 contact hours. Pharmacology contact hours will be designated on your certificate.

Continuing Pharmacy Education

CCO designates this continuing education activity for 10.0 contact hours (1.0 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: UANs will be specific to each topic.

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 10.0 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

Psychologist Continuing Education

Continuing education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

This activity will offer 10.0 continuing education credits for psychologists.

Social Work Continuing Education

As a Jointly Accredited Organization, Clinical Care Options, LLC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 10.0 clinical continuing education credits.

ABMS Approval Statement
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, Medical and Mental Health Issues in Gender Affirming Hormonal Treatments for Transgender and Gender Diverse Patients; Navigating a New Era of Targeted Treatments for Postpartum Depression; Shadows of Wellness: Residual Symptoms in Major Depressive Disorder; Beyond the Breaking Point: Evaluation and Management of Patients in Crisis; Moving Forward: Understanding Tardive Dyskinesia Across the Lifespan; Cultivating Inclusivity: Paving the Path to Improved Diversity in Clinical Trials; Navigating the Frontier of Schizophrenia Treatment: Unveiling Innovations and Ensuring Patient Well-being; Breaking Ground: Exploring the Horizon of Emerging Treatments for PTSD, has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards: 

ABMS Lifelong Learning CME Activity
Psychiatry and Neurology

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, Calming The Storm: Understanding and Managing Agitation in Alzheimer’s-Disease; Decoding Complexity: Best Practices in Identifying and Managing Bipolar Depression with DSM-5-TR Specifiers, has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards: 

ABMS Lifelong Learning CME Activity
Family Medicine
Psychiatry and Neurology

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from Sage Therapeutics, Inc. and Biogen.

Contact Information

For customer support please click here.

Mailing Address:


Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.